Pictet Asset Management (Switzerland)’s Iovance Biotherapeutics IOVA Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$36.4M	Buy	5,175,080 +4,210,788	+437%	+$30.1M	0.04%	348
2023 Q1	$5.89M	Buy	964,292 +524,583	+119%	+$3.62M	0.01%	747
2022 Q4	$2.81M	Sell	439,709 -3,542,635	-89%	-$27.7M	﹤0.01%	868
2022 Q3	$38.2M	Buy	3,982,344 +349,506	+10%	+$4.03M	0.06%	316
2022 Q2	$40.1M	Buy	3,632,838 +1,048,129	+41%	+$13.7M	0.06%	326
2022 Q1	$43M	Buy	2,584,709 +373,577	+17%	+$5.78M	0.05%	343
2021 Q4	$42.2M	Buy	2,211,132 +1,213,057	+122%	+$26.7M	0.04%	374
2021 Q3	$24.6M	Buy	+998,075	New	+$23.5M	0.03%	471

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s IOVA Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Iovance Biotherapeutics (IOVA) stake by 437% in Q2 2023, buying an estimated $30.1M and bringing the position to 5,175,080 shares worth $36.4M. The position accounts for 0.04% of the portfolio, ranked #348.

Pictet Asset Management (Switzerland) first reported a position in IOVA in Q3 2021 and has held it in 8 quarters since. The position peaked at $43M in Q1 2022. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

Pictet Asset Management (Switzerland) held 5,175,080 shares of Iovance Biotherapeutics worth $36.4M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 4,210,788 Iovance Biotherapeutics shares in Q2 2023, an estimated $30.1M.
Iovance Biotherapeutics made up 0.04% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #348 holding.
Pictet Asset Management (Switzerland) first reported a position in Iovance Biotherapeutics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Iovance Biotherapeutics position peaked at $43M in Q1 2022.
219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.